Urinary bladder cancer is uncommon and accounts for only 2% of all malignant solid tumours (1) . Primary treatment mainly consists of radical cystectomy, which is an aggressive approach associated with serious complication rates of up to 30% and treatment-related perioperative mortality of up to 3% (2) (3) (4) . Therefore, bladder-preserving approaches including transurethral resection of bladder tumours (TURBT) followed by radiotherapy and chemotherapy have become more popular. After both radical cystectomy and bladder-preserving approaches, local recurrences are common, occurring in about 20% to 60% of patients (2, 5) . Pelvic lymph node metastases are also quite common (6) . In cases of local or locoregional recurrence, surgical (radical surgery, TURBT) and non-surgical (radiotherapy, radiochemotherapy) are salvage options. Transurethral resection can only be reasonably performed a few times. Thereafter, more radical surgical and non-surgical approaches such as radiotherapy and radiochemotherapy remain. The median age of patients with bladder cancer is over 70 years and many of these patients have significant comorbidities. Those unable to withstand radical surgery are referred for radiotherapy (7) . In the case of primary organ-preserving treatment, radiotherapy was shown to be more effective with the addition of concurrent radiosensitizing chemotherapy (5, 8, 9) . In the case of recurrent bladder cancer, patients are often older and less resilient than at the time of their primary treatment and may be unable to tolerate the addition of chemotherapy. Therefore, the question is whether patients referred to the radiation oncologist for irradiation of recurrent bladder cancer require the combined approach or may be adequately treated with radiotherapy alone. In this study, the impact on overall survival of patients administered chemotherapy concurrently with radiotherapy for locally recurrent bladder cancer was investigated. In addition, nine other factors were analyzed for potential associations with overall survival.
Patients and Methods
Thirty patients irradiated for a local recurrence of bladder cancer between 2001 and 2013 were included in this retrospective study. The total radiation dose ranged from 27.0 to 59.4 Gy (median=59.4 Gy), with doses per fraction of between 1.8 and 3.0 Gy (median=1.8 Gy). The equivalent doses in 2-Gy fractions (EQD2), which takes into account both the total dose and dose per fraction, ranged from 29.3 Gy to 58.4 Gy (median=58.4 Gy) for tumour cell kill (α/β-ratio=10 Gy). Fourteen patients (47%) received concurrent chemotherapy with either cisplatin alone (n=6), paclitaxel alone (n=6), gemcitabine alone (n=1) or cisplatin followed by paclitaxel (n=1). Prior to radiotherapy, patients had undergone surgical interventions which included radical surgery or TURBT. The time interval between primary intervention and radiotherapy of the local recurrence ranged from 0 to 18 years (median=2 years). No patient included in this study was previously irradiated in the pelvic region.
Ten factors were analysed for their potential association with overall survival: gender, age at irradiation (≤76 vs. >76 years, median=76.5 years), period from initial diagnosis of bladder cancer to irradiation of the local recurrence (≤21 vs. >21 months, median=21.5), performance status based on the Karnofsky performance scale (KPS: <80% vs. ≥80%, median=80%), histological grading (G2 vs. G3), pack-years smoked until irradiation (≤40 vs. >40 years), smoking during the radiotherapy (no vs. yes), EQD2 (≤50 vs. ≥52 Gy), interruption of radiotherapy of >5 days (no vs. yes) and administration of concurrent chemotherapy (no vs. yes). For distributions of these factors, please see Table I .
The univariate analyses of overall survival were performed with Kaplan-Meier method followed by log-rank tests (10) . The factors achieving significance (p<0.05) were subsequently analysed in a multivariate manner using a Cox regression model.
Results
The median follow-up time was 14.5 months (range=1-93 months) for all patients and 60.5 months (range=25-83 months) in those who remained alive at the last follow-up visit. For the whole study cohort, the overall survival rates at 1, 3 and 5 years were 50%, 33% and 29%, respectively. On univariate analyses, three factors achieved significance, namely age (p=0.024), KPS (p<0.001) and administration of concurrent chemotherapy (p<0.001, Figure 1 ). Longer overall survival was found in younger patients (≤76 years), patients with a better performance status (KPS ≥80%) and patients receiving concurrent chemotherapy. In addition, higher radiotherapy doses (EQD2 ≥52 Gy) tended to result in improved overall survival (p=0.107). The results of the univariate analyses, including the overall survival rates at 1, 3 and 5 years, are shown in Table II. In the subsequent Cox regression analysis, the positive association between concurrent chemotherapy and survival remained significant (risk ratio=3.82, 95% confidence interval 1.33-11.76, p=0.013). A trend was found for KPS ≥80% (risk ratio=2.50, 95% confidence interval=0.91-7.30, p=0.076). Age did not achieve significance on multivariate analysis (risk ratio=1.63, 95% confidence interval 0.61-4.58, p=0.336).
Discussion
Patients with bladder cancer are uncommon (1) . A considerable number of these patients have a poor prognosis. In order to improve their outcomes, increasing numbers of preclinical and clinical studies are conducted including diagnosis, prognostic factors, development of novel therapies including systemic agents and personalization of treatments ANTICANCER RESEARCH 37: 1485-1488 (2017) 1486 Figure (11) (12) (13) (14) (15) (16) (17) (18) . Such studies cover all stages of disease including primary, locally recurrent and metastatic situations. For primary treatment, surgical resection is considered the standard approach for most situations (2, 6) . However, patients with recurrent or metastatic disease often present with a less favourable general condition and cannot withstand the rigors of aggressive radical cystectomy, which was reported to be associated with up to 30% severe complications and a perioperative death rate of 2-3% (2-4). For these patients, radiotherapy represents a reasonable alternative treatment option. In the case of metastatic disease, radiotherapy is often used for palliation with the intention of alleviating or preventing cancer-related symptoms and maintaining the patient's quality of life (13, 14) . In such cases, radiotherapy is delivered with lower total doses and shorter overall treatment times than those used for curative situations. In the case of a local recurrence of bladder cancer, the prognosis of the patients is generally much more favourable than in the case of distant metastasis. Therefore, higher doses and longer-course regimens are often used with curative intent. Similarly to primary treatment situations, salvage radiotherapy would ideally be supplemented with concurrent chemotherapy (5, 8, 9) . However, the addition of chemotherapy significantly increases treatment toxicity. Often patients with recurrent disease present in worse general condition than patients receiving treatment for their primary tumour; many may not be able to tolerate the addition of chemotherapy. Therefore, it is important to know whether patients irradiated for locally recurrent bladder cancer benefit from concurrent chemotherapy in terms of improved overall survival. To contribute to answering this question, the present study was initiated. The addition of concurrent chemotherapy was associated with significantly improved overall survival when compared to radiotherapy alone on univariate analysis. This finding was also found on multivariate analysis, demonstrating that concurrent chemotherapy was independently associated with improved overall survival. When interpreting our results, one should keep in mind the retrospective study design and the small number of patients included. In order to completely exclude the risk of a hidden selection bias, a properly designed prospective randomized trial is required. However, since patients with recurrent bladder cancer are uncommon, such a prospective trial would be difficult to perform and is unlikely anytime soon.
Comparison of overall survival of patients treated with radiotherapy alone and those patients receiving concurrent radiochemotherapy (Kaplan-Meier analysis with log-rank test).
In addition to concurrent chemotherapy, the KPS showed a strong trend for association with overall survival on multivariate analysis. Since the performance status is generally well-recognized as a predictor of survival in patients with cancer, this finding demonstrates consistency between our cohort and most patients with cancer patients (1) . A higher EQD2 tended to lead to better overall survival on univariate analysis; therefore the use of radiation doses of ≥52 Gy appears to be preferable.
In summary, the addition of concurrent chemotherapy to radiotherapy for locally recurrent bladder cancer resulted in significantly improved overall survival. Therefore, concurrent radiochemotherapy rather than radiotherapy alone should be the preferred approach when reasonable for patients with recurrent bladder cancer, who are not candidates for radical surgery.
